INNOVIVA, INC. Net Income (Loss) Available to Common Stockholders, Diluted
INNOVIVA, INC. (INVA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$83.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$83.42M, a 227.83% decline year-over-year.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $187.99M.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $165.75M, a 596.44% increase year-over-year.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $91.89M, a 7475.43% increase year-over-year.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $279.82M, a 941.78% increase from fiscal 2024.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $26.86M, a 85.96% decline from fiscal 2023.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was $191.30M, a 15.19% decline from fiscal 2022.
- INNOVIVA, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was $225.57M, a 16.64% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$83.42M 10-Q · filed 2026-08-05 | $106.03M 10-Q · filed 2026-08-05 | $270.32M derived: sum of 3 quarters · filed 2026-08-05 | $362.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $187.99M 10-Q · filed 2026-05-06 | $353.74M derived: sum of 2 quarters · filed 2026-05-06 | $445.63M derived: sum of 3 quarters · filed 2026-05-06 | $510.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $165.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $257.64M derived: sum of 2 quarters · filed 2026-02-25 | $322.90M derived: sum of 3 quarters · filed 2026-08-05 | $279.82M 10-K · filed 2026-02-25 |
| 2025-09-30 | $91.89M 10-Q · filed 2025-11-05 | $157.15M derived: sum of 2 quarters · filed 2026-08-05 | $114.07M 10-Q · filed 2025-11-05 | $134.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $65.26M 10-Q · filed 2026-08-05 | $20.25M 10-Q · filed 2026-08-05 | $42.47M derived: sum of 3 quarters · filed 2026-08-05 | $43.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$46.58M 10-Q · filed 2026-05-06 | -$22.78M derived: sum of 2 quarters · filed 2026-05-06 | -$21.57M derived: sum of 3 quarters · filed 2026-05-06 | -$56.26M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $23.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $25.01M derived: sum of 2 quarters · filed 2026-02-25 | -$9.67M derived: sum of 3 quarters · filed 2026-02-25 | $26.86M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-05 | -$33.47M derived: sum of 2 quarters · filed 2025-11-05 | $3.06M 10-Q · filed 2025-11-05 | $70.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$34.69M 10-Q · filed 2025-08-06 | $1.85M 10-Q · filed 2025-08-06 | $69.08M derived: sum of 3 quarters · filed 2026-02-25 | $153.90M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $39.05M 10-Q · filed 2025-05-07 | $103.76M derived: sum of 2 quarters · filed 2026-02-25 | $188.59M derived: sum of 3 quarters · filed 2026-02-25 | $189.87M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $64.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $149.53M derived: sum of 2 quarters · filed 2026-02-25 | $150.81M derived: sum of 3 quarters · filed 2026-02-25 | $191.30M 10-K · filed 2026-02-25 |
| 2023-09-30 | $84.83M 10-Q · filed 2024-11-06 | $86.11M derived: sum of 2 quarters · filed 2024-11-06 | $126.60M 10-Q · filed 2024-11-06 | $57.62M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.28M 10-Q · filed 2024-07-31 | $40.82M 10-Q · filed 2024-07-31 | -$27.21M derived: sum of 3 quarters · filed 2025-02-26 | $241.49M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $37.57M 10-Q · filed 2024-05-08 | -$28.49M derived: sum of 2 quarters · filed 2025-02-26 | $240.21M derived: sum of 3 quarters · filed 2025-02-26 | $244.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$66.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $202.63M derived: sum of 2 quarters · filed 2025-02-26 | $207.23M derived: sum of 3 quarters · filed 2025-02-26 | $225.57M 10-K · filed 2025-02-26 |
| 2022-09-30 | $268.70M 10-Q · filed 2023-11-01 | $273.29M derived: sum of 2 quarters · filed 2023-11-01 | $291.63M 10-Q · filed 2023-11-01 | $303.16M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $4.59M 10-Q · filed 2023-08-02 | $22.93M 10-Q · filed 2023-08-02 | $34.46M derived: sum of 3 quarters · filed 2024-03-05 | $108.09M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $18.34M 10-Q · filed 2023-05-09 | $29.87M derived: sum of 2 quarters · filed 2024-03-05 | $103.49M derived: sum of 3 quarters · filed 2024-03-05 | $193.60M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $11.53M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $85.15M derived: sum of 2 quarters · filed 2024-03-05 | $175.26M derived: sum of 3 quarters · filed 2024-03-05 | $270.59M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $73.62M 10-Q · filed 2022-11-09 | $163.74M derived: sum of 2 quarters · filed 2022-11-09 | $259.06M 10-Q · filed 2022-11-09 | $314.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $90.11M 10-Q · filed 2022-07-27 | $185.44M 10-Q · filed 2022-07-27 | $240.52M derived: sum of 3 quarters · filed 2023-02-28 | $269.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $95.33M 10-Q · filed 2022-05-05 | $150.41M derived: sum of 2 quarters · filed 2023-02-28 | $179.80M derived: sum of 3 quarters · filed 2023-02-28 | $257.83M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $55.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $84.47M derived: sum of 2 quarters · filed 2023-02-28 | $162.50M derived: sum of 3 quarters · filed 2023-02-28 | $229.12M 10-K · filed 2023-02-28 |
| 2020-09-30 | $29.39M 10-Q · filed 2021-10-27 | $107.42M derived: sum of 2 quarters · filed 2021-10-27 | $174.03M 10-Q · filed 2021-10-27 | $221.15M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $78.03M 10-Q · filed 2021-07-29 | $144.65M 10-Q · filed 2021-07-29 | $191.76M derived: sum of 3 quarters · filed 2022-03-17 | $232.73M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $66.62M 10-Q · filed 2021-04-28 | $113.73M derived: sum of 2 quarters · filed 2022-03-17 | $154.70M derived: sum of 3 quarters · filed 2022-03-17 | $193.60M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $47.12M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $88.08M derived: sum of 2 quarters · filed 2022-03-17 | $126.98M derived: sum of 3 quarters · filed 2022-03-17 | $161.94M 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $40.97M 10-Q · filed 2020-10-28 | $79.86M derived: sum of 2 quarters · filed 2020-10-28 | $114.82M 10-Q · filed 2020-10-28 | $380.25M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $38.90M 10-Q · filed 2020-07-29 | $73.86M 10-Q · filed 2020-07-29 | $339.28M derived: sum of 3 quarters · filed 2021-02-25 | $387.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $35.20M 10-Q · filed 2020-04-29 | $300.38M derived: sum of 2 quarters · filed 2021-02-25 | $348.89M derived: sum of 3 quarters · filed 2021-02-25 | $404.93M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $265.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $313.68M derived: sum of 2 quarters · filed 2021-02-25 | $369.72M derived: sum of 3 quarters · filed 2021-02-25 | $400.72M 10-K · filed 2021-02-25 |
| 2018-09-30 | $48.50M 10-Q · filed 2019-10-30 | $104.55M derived: sum of 2 quarters · filed 2019-10-30 | $135.54M 10-Q · filed 2019-10-30 | $195.34M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $56.04M 10-Q · filed 2019-07-24 | $87.04M 10-Q · filed 2019-07-24 | $146.84M derived: sum of 3 quarters · filed 2020-02-19 | $172.01M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $30.99M 10-Q · filed 2019-05-01 | $90.79M derived: sum of 2 quarters · filed 2020-02-19 | $115.97M derived: sum of 3 quarters · filed 2020-02-19 | $152.53M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $59.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $84.98M derived: sum of 2 quarters · filed 2020-02-19 | $121.54M derived: sum of 3 quarters · filed 2020-02-19 | $139.79M 10-K · filed 2020-02-19 |
| 2017-09-30 | $25.18M 10-Q · filed 2018-10-31 | $61.74M derived: sum of 2 quarters · filed 2018-10-31 | $79.99M 10-Q · filed 2018-10-31 | $111.25M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $36.56M 10-Q · filed 2018-07-26 | $54.81M 10-Q · filed 2018-07-26 | $86.07M derived: sum of 3 quarters · filed 2019-02-19 | $102.53M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-03-31 | $18.25M 10-Q · filed 2018-05-04 | $49.51M derived: sum of 2 quarters · filed 2019-02-19 | $65.97M derived: sum of 3 quarters · filed 2019-02-19 | $82.03M derived: sum of 4 quarters · filed 2019-02-19 |
| 2016-12-31 | $31.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $47.72M derived: sum of 2 quarters · filed 2019-02-19 | $63.78M derived: sum of 3 quarters · filed 2019-02-19 | $65.33M 10-K · filed 2019-02-19 |
| 2016-09-30 | $16.46M 10-Q · filed 2017-11-03 | $32.52M derived: sum of 2 quarters · filed 2017-11-03 | $34.06M 10-Q · filed 2017-11-03 | $41.25M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $16.05M 10-Q · filed 2017-08-08 | $19.03M 10-Q · filed 2017-08-08 | $24.79M derived: sum of 3 quarters · filed 2018-02-23 | $20.21M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $4.43M 10-Q · filed 2017-05-05 | $8.74M derived: sum of 2 quarters · filed 2018-02-23 | $4.15M derived: sum of 3 quarters · filed 2018-02-23 | -$3.66M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$283.00K derived: sum of 2 quarters · filed 2018-02-23 | -$8.09M derived: sum of 3 quarters · filed 2018-02-23 | -$18.76M 10-K · filed 2018-02-23 |
| 2015-09-30 | -$4.58M 10-Q · filed 2016-11-03 | -$12.39M derived: sum of 2 quarters · filed 2016-11-03 | -$23.06M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | -$7.81M 10-Q · filed 2016-08-04 | -$18.48M 10-Q · filed 2016-08-04 | ||
| 2014-12-31 | -$168.46M 10-K · filed 2017-02-28 | |||
| 2013-06-30 | -$36.43M 10-Q · filed 2013-08-01 | -$73.79M 10-Q · filed 2013-08-01 | ||
| 2013-03-31 | -$37.36M 10-Q · filed 2013-05-01 | |||
| 2012-09-30 | -$34.69M 10-Q · filed 2012-10-31 | -$71.81M derived: sum of 2 quarters · filed 2013-08-01 | $17.29M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | -$37.12M 10-Q · filed 2013-08-01 | $50.48M 10-Q · filed 2013-08-01 | ||
| 2012-03-31 | $86.09M 10-Q · filed 2013-05-01 | |||
| 2011-09-30 | -$30.63M 10-Q · filed 2012-10-31 | -$55.67M derived: sum of 2 quarters · filed 2012-10-31 | -$78.34M 10-Q · filed 2012-10-31 | |
| 2011-06-30 | -$25.05M 10-Q · filed 2012-08-01 | -$47.71M 10-Q · filed 2012-08-01 | ||
| 2011-03-31 | -$22.67M 10-Q · filed 2012-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |